Atezolizumab is approved following PDC for resected stages II to III NSCLC with a PD-L1 TPS expression of ≥1% (>50% in some countries), while Pembrolizumab has also been approved for stage IB to IIIA rNSCLC, irrespective of PD-L1 TPS expression. Here, CD274 is linked to non-small cell lung carcinoma.